Skip to main navigation Skip to search Skip to main content

Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) plus trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC).

  • David Planchard
  • , Benjamin Besse
  • , Harry Groen
  • , Sayed Hashemi
  • , Julien Mazieres
  • , Tae Min Kim
  • , Elisabeth A. Quoix
  • , Pierre Jean Souquet
  • , Fabrice Barlesi
  • , Christina S. Baik
  • , Liza C. Villaruz
  • , Ronan Joseph Kelly
  • , Shirong Zhang
  • , Monique Tan
  • , Eduard Gasal
  • , Libero Santarpia
  • , Bruce E. Johnson

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
JournalJournal of clinical oncology
Volume38
Issue number15
Publication statusPublished - 20 May 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this